Partanen, A., Kuittinen, O., Turunen, A., Valtola, J., Pyorala, M., Kuitunen, H., Vasala, K., Kuittinen, T., Mantymaa, P., Pelkonen, J., Jantunen, E., & Varmavuo, V. (2021). Blood Graft and Outcome After Autologous Stem Cell Transplantation in Patients With Primary Central Nervous System Lymphoma. Journal Of Hematology, 10(6), 246-254. https://doi.org/10.14740/jh939
Blood graft and outcome after autologous stem cell transplantation in patients with primary central nervous system lymphoma
|Author:||Partanen, Anu1; Kuittinen, Outi2,3,4; Turunen, Antti1;|
1Department of Medicine, Kuopio University Hospital, Kuopio, Finland
2Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
3Department of Oncology, Kuopio University Hospital, Kuopio, Finland
4Department of Oncology, Oulu University Hospital, Oulu, Finland
5Department of Oncology, Central Hospital of Central Finland, Jyvaskyla, Finland
6Eastern Finland Laboratory Centre, Kuopio, Finland
7Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland
8Department of Medicine, North Karelia Hospital District, Joensuu, Finland
9Department of Medicine, Kymenlaakso Central Hospital, Kotka, Finland jCorresponding Author: Anu Partanen, Department of Medicine, Kuopio University
|Online Access:||PDF Full Text (PDF, 0.7 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2022032425184
|Publish Date:|| 2022-03-24
Background: Autologous stem cell transplantation (auto-SCT) is a treatment option for patients with primary central nervous system lymphoma (PCNSL).
Methods: In this prospective multicenter study, the effects of blood graft cellular content on hematologic recovery and outcome were analyzed in 17 PCNSL patients receiving auto-SCT upfront.
Results: The infused viable CD34⁺ cell count > 1.7 × 10⁶/kg correlated with more rapid platelet engraftment (10 vs. 31 days, P = 0.027) and with early neutrophil recovery (day + 15) (5.4 vs. 1.6 × 10⁹/L, P = 0.047). A higher number of total collected CD34⁺ cells > 3.3 × 106/kg infused predicted worse 5-year progression-free survival (PFS) (33% vs. 100%, P = 0.028). In addition, CD3⁺CD8⁺ T cells > 78 × 10⁶/kg in the infused graft impacted negatively on the 5-year PFS (0% vs. 88%, P = 0.016).
Conclusions: The cellular composition of infused graft seems to impact on the hematologic recovery and PFS post-transplant. Further studies are needed to verify the optimal autograft cellular content in PCNSL.
Journal of hematology
|Pages:||246 - 254|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
AP is grateful for the scholarships granted by the Finnish Society of Hematology and the Cancer Foundation of North Savo. A research grant from Sanofi Genzyme for the GOA study is also acknowledged
© The authors. This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited